{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T18:24:52Z","timestamp":1758047092589,"version":"3.44.0"},"reference-count":59,"publisher":"Pharmaceutical Society of Japan","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,9,13]]},"DOI":"10.1248\/bpb.b24-00508","type":"journal-article","created":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:07:53Z","timestamp":1757714873000},"page":"1375-1383","source":"Crossref","is-referenced-by-count":0,"title":["Extracellular CD30 Regulates Brentuximab Vedotin-Induced Cell Death in an Adult T-Cell Leukemia Cell Line"],"prefix":"10.1248","volume":"48","author":[{"given":"Keisuke","family":"Sato","sequence":"first","affiliation":[{"name":"Department of Biochemistry, Faculty of Pharmaceutical Sciences, Fukuoka University, 8\u201319\u20131 Nanakuma, Jonan-ku, Fukuoka 814\u20130180, Japan"},{"name":"Department of Pharmacy, Fukuoka University Hospital, 7\u201345\u20131 Nanakuma, Jonan-ku, Fukuoka 814\u20130180, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Kozako","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Pharmaceutical Sciences, Fukuoka University, 8\u201319\u20131 Nanakuma, Jonan-ku, Fukuoka 814\u20130180, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Pharmaceutical Sciences, Fukuoka University, 8\u201319\u20131 Nanakuma, Jonan-ku, Fukuoka 814\u20130180, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naho","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Fukuoka University, 8\u201319\u20131 Nanakuma, Johnan-ku, Fukuoka 814\u20130180, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Ogata","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fukuoka University Hospital, 7\u201345\u20131 Nanakuma, Jonan-ku, Fukuoka 814\u20130180, Japan"},{"name":"Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University, 8\u201319\u20131 Nanakuma, Jonan-ku, Fukuoka 814\u20130180, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Kamimura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Fukuoka University Hospital, 7\u201345\u20131 Nanakuma, Jonan-ku, Fukuoka 814\u20130180, Japan"},{"name":"Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Fukuoka University, 8\u201319\u20131 Nanakuma, Johnan-ku, Fukuoka 814\u20130180, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Hematology and Infectious Diseases, Department of Medicine, Fukuoka University, 7\u201345\u20131 Nanakuma, Jonan-ku, Fukuoka 814\u20130180, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Takamatsu","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Hematology and Infectious Diseases, Department of Medicine, Fukuoka University, 7\u201345\u20131 Nanakuma, Jonan-ku, Fukuoka 814\u20130180, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Takemoto","sequence":"additional","affiliation":[{"name":"JURAKU Internal Medicine Clinic, 1\u201311\u201331 Nishihara,Higashi-ku, Kumamoto 861\u20138029, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-Ichiro","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Pharmaceutical Sciences, Fukuoka University, 8\u201319\u20131 Nanakuma, Jonan-ku, Fukuoka 814\u20130180, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Yoshida M. Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. <i>Annu. Rev. Immunol.<\/i>, <b>19<\/b>, 475\u2013496 (2001).","DOI":"10.1146\/annurev.immunol.19.1.475"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Uchiyama T. Human T cell leukemia virus type I (HTLV-I) and human diseases. <i>Annu. Rev. Immunol.<\/i>, <b>15<\/b>, 15\u201337 (1997).","DOI":"10.1146\/annurev.immunol.15.1.15"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma\u2014a report from the lymphoma study group (1984-87). <i>Br. J. Haematol.<\/i>, <b>79<\/b>, 428\u2013437 (1991).","DOI":"10.1111\/j.1365-2141.1991.tb08051.x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Katsuya H, Yamanaka T, Ishitsuka K, <i>et al<\/i>. Prognostic index for acute- and lymphoma-type adult T-cell leukemia\/lymphoma. <i>J. Clin. Oncol.<\/i>, <b>30<\/b>, 1635\u20131640 (2012).","DOI":"10.1200\/JCO.2011.38.2101"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Fukushima T, Nomura S, Shimoyama M, <i>et al<\/i>. Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A). <i>Br. J. Haematol.<\/i>, <b>166<\/b>, 739\u2013748 (2014).","DOI":"10.1111\/bjh.12962"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Ito S, Iwanaga M, Nosaka K, Imaizumi Y, Ishitsuka K, Amano M, Utsunomiya A, Tokura Y, Watanabe T, Uchimaru K, Tsukasaki K. Epidemiology of adult T-cell leukemia-lymphoma in Japan: An updated analysis, 2012-2013. <i>Cancer Sci.<\/i>, <b>112<\/b>, 4346\u20134354 (2021).","DOI":"10.1111\/cas.15097"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Kozako T, Yoshimitsu M, Fujiwara H, Masamoto I, Horai S, White Y, Akimoto M, Suzuki S, Matsushita K, Uozumi K, Tei C, Arima N. PD-1\/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia\/lymphoma patients. <i>Leukemia<\/i>, <b>23<\/b>, 375\u2013382 (2009).","DOI":"10.1038\/leu.2008.272"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Tagaya Y, Matsuoka M, Gallo R. 40 years of the human T-cell leukemia virus: past, present, and future. <i>F1000Res.<\/i>, <b>8<\/b>, 8 (2019).","DOI":"10.12688\/f1000research.17479.1"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Katsuya H, Ishitsuka K, Utsunomiya A, <i>et al<\/i>. Treatment and survival among 1594 patients with ATL. <i>Blood<\/i>, <b>126<\/b>, 2570\u20132577 (2015).","DOI":"10.1182\/blood-2015-03-632489"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Ishitsuka K, Yurimoto S, Tsuji Y, Iwabuchi M, Takahashi T, Tobinai K. Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma. <i>Eur. J. Haematol.<\/i>, <b>102<\/b>, 407\u2013415 (2019).","DOI":"10.1111\/ejh.13220"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schaadt M, Diehl V. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin&apos;s disease and a subset of normal lymphoid cells. <i>Nature<\/i>, <b>299<\/b>, 65\u201367 (1982).","DOI":"10.1038\/299065a0"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Falini B, Pileri S, Pizzolo G, Durkop H, Flenghi L, Stirpe F, Martelli MF, Stein H. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. <i>Blood<\/i>, <b>85<\/b>, 1\u201314 (1995).","DOI":"10.1182\/blood.V85.1.1.bloodjournal8511"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Higuchi M, Matsuda T, Mori N, Yamada Y, Horie R, Watanabe T, Taka hashi M, Oie M, Fujii M. Elevated expression of CD30 in adult T-cell leukemia cell lines: possible role in constitutive NF-\u03baB activation. <i>Retrovirology<\/i>, <b>2<\/b>, 29 (2005).","DOI":"10.1186\/1742-4690-2-29"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. <i>Nat. Rev. Cancer<\/i>, <b>8<\/b>, 11\u201323 (2008).","DOI":"10.1038\/nrc2291"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Ohtsuka E, Kikuchi H, Nasu M, Takitasonoda Y, Fujii H, Yokoyama S. Clinicopathological features of adult T-cell leukemia with CD30 antigen expression. <i>Leuk. Lymphoma<\/i>, <b>15<\/b>, 303\u2013310 (1994).","DOI":"10.3109\/10428199409049728"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Kurts C, Carbone FR, Krummel MF, Koch KM, Miller J, Heath WR. Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells. <i>Nature<\/i>, <b>398<\/b>, 341\u2013344 (1999).","DOI":"10.1038\/18692"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Nakashima M, Yamochi T, Watanabe M, Uchimaru K, Utsunomiya A, Higashihara M, Watanabe T, Horie R. CD30 Characterizes polylobated lymphocytes and disease progression in HTLV-1-infected individuals. <i>Clin. Cancer Res.<\/i>, <b>24<\/b>, 5445\u20135457 (2018).","DOI":"10.1158\/1078-0432.CCR-18-0268"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Younes A. CD30-targeted antibody therapy. <i>Curr. Opin. Oncol.<\/i>, <b>23<\/b>, 587\u2013593 (2011).","DOI":"10.1097\/CCO.0b013e32834bb8a7"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Huebner D, Kennedy DA, Shustov AR. Brentuximab vedotin in the front-line treatment of patients with CD30<sup>+<\/sup> peripheral T-cell lymphomas: results of a phase I study. <i>J. Clin. Oncol.<\/i>, <b>32<\/b>, 3137\u20133143 (2014).","DOI":"10.1200\/JCO.2013.54.2456"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, DeBlanc RL, Gearing RP, Bovee TD, Siegall CB, Francisco JA, Wahl AF, Meyer DL, Senter PD. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. <i>Nat. Biotechnol.<\/i>, <b>21<\/b>, 778\u2013784 (2003).","DOI":"10.1038\/nbt832"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Katz J, Janik JE, Younes A. Brentuximab vedotin (SGN-35). Clin. <i>Cancer Res.<\/i>, <b>17<\/b>, 6428\u20136436 (2011).","DOI":"10.1158\/1078-0432.CCR-11-0488"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Maeda N, Muta H, Oflazoglu E, Yoshikai Y. Susceptibility of human T-cell leukemia virus type I-infected cells to humanized anti-CD30 monoclonal antibodies <i>in vitro<\/i> and <i>in vivo<\/i>. <i>Cancer Sci.<\/i>, <b>101<\/b>, 224\u2013230 (2010).","DOI":"10.1111\/j.1349-7006.2009.01354.x"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Tsukasaki K, Mar\u00e7ais A, Nasr R, Kato K, Fukuda T, Hermine O, Bazarbachi A. Diagnostic approaches and established treatments for adult T cell leukemia lymphoma. <i>Front. Microbiol.<\/i>, <b>11<\/b>, 1207 (2020).","DOI":"10.3389\/fmicb.2020.01207"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Ishitsuka K. Diagnosis and management of adult T-cell leukemia\/lymphoma. <i>Semin. Hematol.<\/i>, <b>58<\/b>, 114\u2013122 (2021).","DOI":"10.1053\/j.seminhematol.2021.02.005"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Takemoto S, Iwanaga M, Sagara Y, Watanabe T. Plasma soluble CD30 as a possible marker of adult T-cell leukemia in HTLV-1 carriers: a nested case-control study. <i>Asian Pac. J. Cancer Prev.<\/i>, <b>16<\/b>, 8253\u20138258 (2015).","DOI":"10.7314\/APJCP.2015.16.18.8253"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Nishioka C, Takemoto S, Kataoka S, Yamanaka S, Moriki T, Shoda M, Watanabe T, Taguchi H. Serum level of soluble CD30 correlates with the aggressiveness of adult T-cell leukemia\/lymphoma. <i>Cancer Sci.<\/i>, <b>96<\/b>, 810\u2013815 (2005).","DOI":"10.1111\/j.1349-7006.2005.00106.x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Jacobsen ED, Sharman JP, Oki Y, Advani RH, Winter JN, Bello CM, Spitzer G, Palanca-Wessels MC, Kennedy DA, Levine P, Yang J, Bartlett NL. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression. <i>Blood<\/i>, <b>125<\/b>, 1394\u20131402 (2015).","DOI":"10.1182\/blood-2014-09-598763"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O\u2019Connor OA, Siddiqi T, Kennedy DA, Oki Y. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. <i>Blood<\/i>, <b>123<\/b>, 3095\u20133100 (2014).","DOI":"10.1182\/blood-2013-12-542142"},{"key":"29","unstructured":"29) Ratiorn P, Shigeki T, Michihiro H, Fumio K, Yoshio H. Clinical value of serum soluble CD30 levels in adult T-cell leukemia\/lymphoma. <i>Journal of Hematology &amp; Thromboembolic Diseases<\/i>, <b>2<\/b>, 1000167 (2014)."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Khokha R, Murthy A, Weiss A. Metalloproteinases and their natural inhibitors in inflammation and immunity. <i>Nat. Rev. Immunol.<\/i>, <b>13<\/b>, 649\u2013665 (2013).","DOI":"10.1038\/nri3499"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Vandenbroucke RE, Libert C. Is there new hope for therapeutic matrix metalloproteinase inhibition? <i>Nat. Rev. Drug Discov.<\/i>, <b>13<\/b>, 904\u2013927 (2014).","DOI":"10.1038\/nrd4390"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Kato T, Hagiyama M, Ito A. Renal ADAM10 and 17: their physiological and medical meanings. <i>Front. Cell Dev. Biol.<\/i>, <b>6<\/b>, 153 (2018).","DOI":"10.3389\/fcell.2018.00153"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Eichenauer DA, Simhadri VL, von Strandmann EP, Ludwig A, Matthews V, Reiners KS, von Tresckow B, Saftig P, Rose-John S, Engert A, Hansen HP. ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy <i>in vitro<\/i>. <i>Cancer Res.<\/i>, <b>67<\/b>, 332\u2013338 (2007).","DOI":"10.1158\/0008-5472.CAN-06-2470"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Hansen HP, Dietrich S, Kisseleva T, Mokros T, Mentlein R, Lange HH, Murphy G, Lemke H. CD30 shedding from Karpas 299 lymphoma cells is mediated by TNF-\u03b1-converting enzyme. <i>J. Immunol.<\/i>, <b>165<\/b>, 6703\u20136709 (2000).","DOI":"10.4049\/jimmunol.165.12.6703"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Ebsen H, Schroder A, Kabelitz D, Janssen O. Differential surface expression of ADAM10 and ADAM17 on human T lymphocytes and tumor cells. <i>PLOS ONE<\/i>, <b>8<\/b>, e76853 (2013).","DOI":"10.1371\/journal.pone.0076853"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Hansen HP, Kisseleva T, Kobarg J, Horn-Lohrens O, Havsteen B, Lemke H. A zinc metalloproteinase is responsible for the release of CD30 on human tumor cell lines. <i>Int. J. Cancer<\/i>, <b>63<\/b>, 750\u2013756 (1995).","DOI":"10.1002\/ijc.2910630524"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Arima N, Arimura K, Tokito Y, Sakaki Y, Matsushita K, Orihara K, Akimoto M, Ozaki A, Kukita T, Hagiwara T, Hamada H, Tei C. HTLV-I Tax protein inhibits apoptosis induction but not G1 arrest by pyrrolidinedithiocarbamate, an anti-oxidant, in adult T cell leukemia cells. <i>Exp. Hematol.<\/i>, <b>32<\/b>, 195\u2013201 (2004).","DOI":"10.1016\/j.exphem.2003.11.008"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Suzuki S, Hourai S, Uozumi K, Uchida Y, Yoshimitsu M, Miho H, Arima N, Ueno S, Ishitsuka K. Gamma-secretase inhibitor does not induce cytotoxicity in adult T-cell leukemia cell lines despite NOTCH1 expression. <i>BMC Cancer<\/i>, <b>22<\/b>, 1065 (2022).","DOI":"10.1186\/s12885-022-10003-w"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Kozako T, Suzuki T, Yoshimitsu M, Uchida Y, Kuroki A, Aikawa A, Honda SI, Arima N, Soeda S. Novel small-molecule SIRT1 inhibitors induce cell death in adult T-cell leukaemia cells. <i>Sci. Rep.<\/i>, <b>5<\/b>, 11345 (2015).","DOI":"10.1038\/srep11345"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Kozako T, Aikawa A, Shoji T, Fujimoto T, Yoshimitsu M, Shirasawa S, Tanaka H, Honda SI, Shimeno H, Arima N, Soeda S. High expression of the longevity gene product SIRT1 and apoptosis induction by sirtinol in adult T-cell leukemia cells. <i>Int. J. Cancer<\/i>, <b>131<\/b>, 2044\u20132055 (2012).","DOI":"10.1002\/ijc.27481"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Aikawa A, Kozako T, Uchida Y, Yoshimitsu M, Ishitsuka K, Ohsugi T, Honda SI. Cell death induced by dorsomorphin in adult T-cell leukemia\/lymphoma is AMPK-independent. <i>FEBS J.<\/i>, <b>287<\/b>, 4005\u20134015 (2020).","DOI":"10.1111\/febs.15239"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Kozako T, Mellini P, Ohsugi T, Aikawa A, Uchida YI, Honda SI, Suzuki T. Novel small molecule SIRT2 inhibitors induce cell death in leukemic cell lines. <i>BMC Cancer<\/i>, <b>18<\/b>, 791 (2018).","DOI":"10.1186\/s12885-018-4710-1"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Kozako T, Aikawa A, Ohsugi T, Uchida YI, Kato N, Sato K, Ishitsuka K, Yoshimitsu M, Honda SI. High expression of NAMPT in adult T-cell leukemia\/lymphoma and anti-tumor activity of a NAMPT inhibitor. <i>Eur. J. Pharmacol.<\/i>, <b>865<\/b>, 172738 (2019).","DOI":"10.1016\/j.ejphar.2019.172738"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Nakai W, Yoshida T, Diez D, Miyatake Y, Nishibu T, Imawaka N, Naruse K, Sadamura Y, Hanayama R. A novel affinity-based method for the isolation of highly purified extracellular vesicles. <i>Sci. Rep.<\/i>, <b>6<\/b>, 33935 (2016).","DOI":"10.1038\/srep33935"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Yoshioka Y, Kosaka N, Konishi Y, Ohta H, Okamoto H, Sonoda H, Nonaka R, Yamamoto H, Ishii H, Mori M, Furuta K, Nakajima T, Hayashi H, Sugisaki H, Higashimoto H, Kato T, Takeshita F, Ochiya T. Ultra-sensitive liquid biopsy of circulating extracellular vesicles using ExoScreen. <i>Nat. Commun.<\/i>, <b>5<\/b>, 3591 (2014).","DOI":"10.1038\/ncomms4591"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Urabe F, Kosaka N, Sawa Y, Yamamoto Y, Ito K, Yamamoto T, Kimura T, Egawa S, Ochiya T. miR-26a regulates extracellular vesicle secretion from prostate cancer cells <i>via<\/i> targeting SHC4, PFDN4, and CHORDC1. <i>Sci. Adv.<\/i>, <b>6<\/b>, eaay3051 (2020).","DOI":"10.1126\/sciadv.aay3051"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Lundgren JL, Ahmed S, Schedin-Weiss S, Gouras GK, Winblad B, Tjernberg LO, Frykman S. ADAM10 and BACE1 are localized to synaptic vesicles. <i>J. Neurochem.<\/i>, <b>135<\/b>, 606\u2013615 (2015).","DOI":"10.1111\/jnc.13287"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Lorenzen I, Lokau J, Korpys Y, Oldefest M, Flynn CM, Kunzel U, Garbers C, Freeman M, Gr\u00f6tzinger J, D\u00fcsterh\u00f6ft S. Control of ADAM17 activity by regulation of its cellular localisation. <i>Sci. Rep.<\/i>, <b>6<\/b>, 35067 (2016).","DOI":"10.1038\/srep37364"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Kozako T, Kato N, Ohsugi T, Uchida YI, Yoshimitsu M, Ishitsuka K, Higaki Y, Sato H, Aikawa A, Honda SI. SRT1720 induces SIRT1-independent cell death in adult T-cell leukemia\/lymphoma. <i>FEBS J.<\/i>, <b>289<\/b>, 3477\u20133488 (2022).","DOI":"10.1111\/febs.16353"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Ciravolo V, Huber V, Ghedini GC, Venturelli E, Bianchi F, Campiglio M, Morelli D, Villa A, Della Mina P, Menard S, Filipazzi P, Rivoltini L, Tagliabue E, Pupa SM. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. <i>J. Cell. Physiol.<\/i>, <b>227<\/b>, 658\u2013667 (2012).","DOI":"10.1002\/jcp.22773"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Barok M, Puhka M, Yazdi N, Joensuu H. Extracellular vesicles as modifiers of antibody-drug conjugate efficacy. <i>J. Extracell. Vesicles<\/i>, <b>10<\/b>, e12070 (2021).","DOI":"10.1002\/jev2.12070"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Mori N, Sato H, Hayashibara T, Senba M, Hayashi T, Yamada Y, Kamihira S, Ikeda S, Yamasaki Y, Morikawa S, Tomonaga M, Geleziunas R, Yamamoto N. Human T-cell leukemia virus type I Tax transactivates the matrix metalloproteinase-9 gene: potential role in mediating adult T-cell leukemia invasiveness. <i>Blood<\/i>, <b>99<\/b>, 1341\u20131349 (2002).","DOI":"10.1182\/blood.V99.4.1341"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Nakachi S, Nakazato T, Ishikawa C, Kimura I, Mann DA, Senba M, Masuzaki H, Mori N. Human T-cell leukemia virus type 1 Tax transactivates the matrix metalloproteinase 7 gene <i>via<\/i> JunD\/AP-1 signaling. <i>Biochim. Biophys. Acta<\/i>, <b>1813<\/b>, 731\u2013741 (2011).","DOI":"10.1016\/j.bbamcr.2011.02.002"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Huovila APJ, Turner AJ, Pelto-Huikko M, Karkkainen L, Ortiz RM. Shedding light on ADAM metalloproteinases. <i>Trends Biochem. Sci.<\/i>, <b>30<\/b>, 413\u2013422 (2005).","DOI":"10.1016\/j.tibs.2005.05.006"},{"key":"55","unstructured":"55) Castillo LEM, Campuzano-Zuluaga G, Toomey NL, Pimentel A, Alencar AJ, Chapman-Fredricks JR, Ramos JC. Targeting CD30 expression in adult T-cell leukemia-lymphoma (ATLL). <i>Blood<\/i>, <b>130<\/b> (Suppl. 1), 374 (2017)."},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Karube K, Kakimoto Y, Tonozuka Y, Ohshima K. The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas. <i>Expert Rev. Hematol.<\/i>, <b>14<\/b>, 777\u2013787 (2021).","DOI":"10.1080\/17474086.2021.1955344"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Hansen HP, Paes Leme AF, Hallek M. Role of ADAM10 as a CD30 Sheddase in classical Hodgkin lymphoma. <i>Front. Immunol.<\/i>, <b>11<\/b>, 398 (2020).","DOI":"10.3389\/fimmu.2020.00398"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Liu-Kreyche P, Shen H, Marino AM, Iyer RA, Humphreys WG, Lai Y. Lysosomal P-gp-MDR1 confers drug resistance of brentuximab vedotin and its cytotoxic payload monomethyl auristatin E in tumor cells. <i>Front. Pharmacol.<\/i>, <b>10<\/b>, 749 (2019).","DOI":"10.3389\/fphar.2019.00749"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Chen R, Herrera AF, Hou J, Chen L, Wu J, Guo Y, Synold TW, Ngo VN, Puverel S, Mei M, Popplewell L, Yi S, Song JY, Tao S, Wu X, Chan WC, Forman SJ, Kwak LW, Rosen ST, Newman EM. Inhibition of MDR1 overcomes resistance to brentuximab vedotin in Hodgkin Lymphoma. <i>Clin. Cancer Res.<\/i>, <b>26<\/b>, 1034\u20131044 (2020).","DOI":"10.1158\/1078-0432.CCR-19-1768"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/9\/48_b24-00508\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T03:59:03Z","timestamp":1757735943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/9\/48_b24-00508\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,13]]},"references-count":59,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b24-00508","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,13]]},"article-number":"b24-00508"}}